Cargando…
Identification of potential metabolite markers for colon cancer and rectal cancer using serum metabolomics
BACKGROUND: To determine the metabolic characteristics of patients with colon cancer (CC) and rectal cancer (RC) using gas chromatography‐mass spectrometry (GC‐MS)‐based metabolomics. METHODS: In this study, serum samples were collected from 22 CC patients and 23 RC patients preoperatively and posto...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439421/ https://www.ncbi.nlm.nih.gov/pubmed/32281150 http://dx.doi.org/10.1002/jcla.23333 |
_version_ | 1783572978087231488 |
---|---|
author | Wu, Jianping Wu, Minyi Wu, Qianxia |
author_facet | Wu, Jianping Wu, Minyi Wu, Qianxia |
author_sort | Wu, Jianping |
collection | PubMed |
description | BACKGROUND: To determine the metabolic characteristics of patients with colon cancer (CC) and rectal cancer (RC) using gas chromatography‐mass spectrometry (GC‐MS)‐based metabolomics. METHODS: In this study, serum samples were collected from 22 CC patients and 23 RC patients preoperatively and postoperatively and 45 healthy volunteers (HVs), and subjected to metabolomics analysis by GC‐MS. Differential metabolites in the preoperative RC and CC samples and HVs were identified as potential biomarkers and evaluated for their utilities by receiver operating characteristic analyses. RESULTS: The different metabolic markers between CC and RC patients were identified, which may assist in distinguishing the two types of cancers. The area under the curve (AUC) was 0.805 for combination of d‐glucose and d‐mannose for CC diagnosis, and 0.889 for combination of 2‐aminobutanoic acid, 3‐hydroxypyridine, d‐glucose, d‐mannose, isoleucine, l‐tryptophan, urea, and uric acid for RC diagnosis. The combinations of metabolite markers showed a better predictability than CEA and CA199 two commonly used protein markers for CRC diagnosis in clinical practice. Combining the metabolite markers with these two protein markers effectively improved the diagnostic accuracy with the AUC reaching 0.936 and 0.937 for CC and RC diagnosis, respectively. CONCLUSIONS: Metabolic profiles are different in the blood samples between CC and RC patients. The study has established a panel of metabolic markers as a predictive and multiplexing signature for CC and RC diagnosis. |
format | Online Article Text |
id | pubmed-7439421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74394212020-08-21 Identification of potential metabolite markers for colon cancer and rectal cancer using serum metabolomics Wu, Jianping Wu, Minyi Wu, Qianxia J Clin Lab Anal Research Articles BACKGROUND: To determine the metabolic characteristics of patients with colon cancer (CC) and rectal cancer (RC) using gas chromatography‐mass spectrometry (GC‐MS)‐based metabolomics. METHODS: In this study, serum samples were collected from 22 CC patients and 23 RC patients preoperatively and postoperatively and 45 healthy volunteers (HVs), and subjected to metabolomics analysis by GC‐MS. Differential metabolites in the preoperative RC and CC samples and HVs were identified as potential biomarkers and evaluated for their utilities by receiver operating characteristic analyses. RESULTS: The different metabolic markers between CC and RC patients were identified, which may assist in distinguishing the two types of cancers. The area under the curve (AUC) was 0.805 for combination of d‐glucose and d‐mannose for CC diagnosis, and 0.889 for combination of 2‐aminobutanoic acid, 3‐hydroxypyridine, d‐glucose, d‐mannose, isoleucine, l‐tryptophan, urea, and uric acid for RC diagnosis. The combinations of metabolite markers showed a better predictability than CEA and CA199 two commonly used protein markers for CRC diagnosis in clinical practice. Combining the metabolite markers with these two protein markers effectively improved the diagnostic accuracy with the AUC reaching 0.936 and 0.937 for CC and RC diagnosis, respectively. CONCLUSIONS: Metabolic profiles are different in the blood samples between CC and RC patients. The study has established a panel of metabolic markers as a predictive and multiplexing signature for CC and RC diagnosis. John Wiley and Sons Inc. 2020-04-13 /pmc/articles/PMC7439421/ /pubmed/32281150 http://dx.doi.org/10.1002/jcla.23333 Text en © 2020 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Articles Wu, Jianping Wu, Minyi Wu, Qianxia Identification of potential metabolite markers for colon cancer and rectal cancer using serum metabolomics |
title | Identification of potential metabolite markers for colon cancer and rectal cancer using serum metabolomics |
title_full | Identification of potential metabolite markers for colon cancer and rectal cancer using serum metabolomics |
title_fullStr | Identification of potential metabolite markers for colon cancer and rectal cancer using serum metabolomics |
title_full_unstemmed | Identification of potential metabolite markers for colon cancer and rectal cancer using serum metabolomics |
title_short | Identification of potential metabolite markers for colon cancer and rectal cancer using serum metabolomics |
title_sort | identification of potential metabolite markers for colon cancer and rectal cancer using serum metabolomics |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439421/ https://www.ncbi.nlm.nih.gov/pubmed/32281150 http://dx.doi.org/10.1002/jcla.23333 |
work_keys_str_mv | AT wujianping identificationofpotentialmetabolitemarkersforcoloncancerandrectalcancerusingserummetabolomics AT wuminyi identificationofpotentialmetabolitemarkersforcoloncancerandrectalcancerusingserummetabolomics AT wuqianxia identificationofpotentialmetabolitemarkersforcoloncancerandrectalcancerusingserummetabolomics |